发明名称 |
Interferon receptor 1 antibodies and their uses |
摘要 |
The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention. |
申请公布号 |
US9453077(B2) |
申请公布日期 |
2016.09.27 |
申请号 |
US201313890494 |
申请日期 |
2013.05.09 |
申请人 |
E. R. SQUIBB & SONS, L.L.C. |
发明人 |
Cardarelli Josephine M.;Witte Alison;Srinivasan Mohan |
分类号 |
A61K39/00;C12P21/08;C07K16/28;A61K47/48 |
主分类号 |
A61K39/00 |
代理机构 |
Baker Botts L.L.P. |
代理人 |
Baker Botts L.L.P. |
主权项 |
1. An isolated monoclonal antibody, or antigen-binding portion thereof, which specifically binds to human interferon alpha receptor 1 (IFNAR-1), wherein the antibody or antigen-binding portion thereof is selected from the group consisting of:
(a) an antibody, or antigen-binding portion thereof, comprising: a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 1; a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:5; a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:9; a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 13; a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 17; and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:21; (b) an antibody, or antigen-binding portion thereof, comprising: a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:2; a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:6; a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 10; a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 14; a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 18; and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:22; and (c) an antibody, or antigen-binding portion thereof, comprising: a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:4; a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:8; a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 12; a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 16; a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:20; and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:24. |
地址 |
Princeton NJ US |